Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer

[1]  N. Mackman,et al.  Tissue Factor and Extracellular Vesicles: Activation of Coagulation and Impact on Survival in Cancer , 2021, Cancers.

[2]  T. Billiar,et al.  Platelet TLR4-ERK5 Axis Facilitates NET-Mediated Capturing of Circulating Tumor Cells and Distant Metastasis after Surgical Stress , 2021, Cancer Research.

[3]  W. Wick,et al.  Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model. , 2020, Blood.

[4]  C. Dabrosin,et al.  Platelet activation in situ in breasts at high risk of cancer: relationship with mammographic density and estradiol. , 2020, The Journal of clinical endocrinology and metabolism.

[5]  R. Muschel,et al.  Platelets and Metastasis: New Implications of an Old Interplay , 2020, Frontiers in Oncology.

[6]  J. Harvey,et al.  Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial , 2020, Trials.

[7]  G. Landberg,et al.  Breast cancer stromal clotting activation (Tissue Factor and thrombin): A pre‐invasive phenomena that is prognostic in invasion , 2020, Cancer medicine.

[8]  Leonie L. Zeune,et al.  Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival , 2020, British Journal of Cancer.

[9]  yongjun zhang,et al.  The association of D-dimer with clinicopathological features of breast cancer and its usefulness in differential diagnosis: A systematic review and meta-analysis , 2019, PloS one.

[10]  M. Levi.  Disseminated Intravascular Coagulation in Cancer: An Update , 2019, Seminars in Thrombosis and Hemostasis.

[11]  Stuart Walker.  Local. , 2018, AORN journal.

[12]  G. Ciliberto,et al.  Observational study of coagulation activation in early breast cancer: development of a prognostic model based on data from the real world setting , 2018, Journal of Translational Medicine.

[13]  J. Reuben,et al.  Circulating tumor cells and coagulation-Minireview. , 2017, Critical reviews in oncology/hematology.

[14]  C. Kirwan,et al.  Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer , 2016, Clinical and Translational Oncology.

[15]  J. Reuben,et al.  Relationship between Circulating Tumor Cells, Blood Coagulation, and Urokinase‐Plasminogen‐Activator System in Early Breast Cancer Patients , 2015, The breast journal.

[16]  A. Sieuwerts,et al.  Circulating tumour cells and lung microvascular tumour cell retention in patients with metastatic breast and cervical cancer. , 2015, Cancer letters.

[17]  T. Fehm,et al.  Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.

[18]  P. V. van Dam,et al.  Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes , 2013, British Journal of Cancer.

[19]  A. Falanga,et al.  Coagulation and cancer: biological and clinical aspects , 2013, Journal of thrombosis and haemostasis : JTH.

[20]  S. Sleijfer,et al.  External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study , 2011, Cytometry. Part B, Clinical cytometry.

[21]  P. V. van Dam,et al.  Circulating tumour cell detection: a direct comparison between the CellSearch System, the AdnaTest and CK-19/mammaglobin RT–PCR in patients with metastatic breast cancer , 2009, British Journal of Cancer.

[22]  V. Valero,et al.  Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients , 2009, British Journal of Cancer.

[23]  H. Chew,et al.  Incidence of venous thromboembolism and the impact on survival in breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. van Marck,et al.  Arterio-venous gradients of IL-6, plasma and serum VEGF and D-dimers in human cancer , 2002, British Journal of Cancer.

[25]  E. van Marck,et al.  The importance of the VEGF-load in platelets in cancer patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  P. V. van Dam,et al.  Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer , 2002, British Journal of Cancer.

[27]  D. Berry,et al.  Plasma D-dimer levels in operable breast cancer patients correlate with clinical stage and axillary lymph node status. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  P. Vermeulen,et al.  Blood platelets and serum VEGF in cancer patients , 1999, British Journal of Cancer.

[29]  J. Weyler,et al.  Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer , 1999, British Journal of Cancer.

[30]  J. Wilcox,et al.  Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer. , 1998, The American journal of pathology.

[31]  H. Dvorak,et al.  Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. , 1989, Biochimica et biophysica acta.

[32]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[33]  A. Al-Mehdi,et al.  Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis , 2000, Nature Medicine.

[34]  P. Vermeulen,et al.  Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. , 1997, British Journal of Cancer.